Designing vaccines for the twenty-first century society.
- Published: 23 Jan 2014 Journal: Frontiers in Immunology (issn: 1664-3224,
Copyright policy)
- Publisher: Frontiers Media S.A.
- Novartis (Switzerland) Switzerland
1 Willis NJ. Edward Jenner and the eradication of smallpox. Scott Med J (1997) 42:118–21.
2 Lakhani S. Early clinical pathologists: Edward Jenner (1749-1823). J Clin Pathol (1992) 45:756–8.10.1136/jcp.45.9.756 [OpenAIRE] [DOI]
3 Kaushik DK Sehgal D. Developing antibacterial vaccines in genomics and proteomics era. Scand J Immunol (2008) 67:544–52.10.1111/j.1365-3083.2008.02107.x 18397199 [OpenAIRE] [PubMed] [DOI]
4 Rappuoli R Miller HI Falkow S. Medicine. The intangible value of vaccination. Science (2002) 297:937–9.10.1126/science.1075173 [OpenAIRE] [DOI]
5 Plotkin SA. Vaccines: past, present and future. Nat Med (2005) 11:S5–11.10.1038/nm1209 15812490 [OpenAIRE] [PubMed] [DOI]
6 Rappuoli R. From Pasteur to genomics: progress and challenges in infectious diseases. Nat Med (2004) 10:1177–85.10.1038/nm1129 15516917 [OpenAIRE] [PubMed] [DOI]
7 Makela PH Peltola H Kayhty H Jousimies H Pettay O Ruoslahti E Polysaccharide vaccines of group A Neisseria meningtitidis and Haemophilus influenzae type b: a field trial in Finland. J Infect Dis (1977) 136(Suppl):S43–50.10.1093/infdis/136.Supplement.S43 [OpenAIRE] [DOI]
8 Peltola H Makela H Kayhty H Jousimies H Herva E Hallstrom K Clinical efficacy of meningococcus group A capsular polysaccharide vaccine in children three months to five years of age. N Engl J Med (1977) 297:686–91.10.1056/NEJM197709292971302 408682 [OpenAIRE] [PubMed] [DOI]
9 Lesinski GB Westerink MA. Novel vaccine strategies to T-independent antigens. J Microbiol Methods (2001) 47:135–49.10.1016/S0167-7012(01)00290-1 11576678 [PubMed] [DOI]
10 Conaty S Watson L Dinnes J Waugh N. The effectiveness of pneumococcal polysaccharide vaccines in adults: a systematic review of observational studies and comparison with results from randomised controlled trials. Vaccine (2004) 22:3214–24.10.1016/j.vaccine.2003.08.050 15297076 [OpenAIRE] [PubMed] [DOI]
11 Lepow ML Goldschneider I Gold R Randolph M Gotschlich EC. Persistence of antibody following immunization of children with groups A and C meningococcal polysaccharide vaccines. Pediatrics (1977) 60:673–80.411104 [PubMed]
12 Peltola H Kayhty H Virtanen M Makela PH. Prevention of Hemophilus influenzae type b bacteremic infections with the capsular polysaccharide vaccine. N Engl J Med (1984) 310:1561–6.10.1056/NEJM198406143102404 6610125 [OpenAIRE] [PubMed] [DOI]
13 Makela PH Kayhty H. Evolution of conjugate vaccines. Expert Rev Vaccines (2002) 1:399–410.10.1586/14760584.1.3.399 [OpenAIRE] [DOI]
14 Lai Z Schreiber JR. Antigen processing of glycoconjugate vaccines; the polysaccharide portion of the pneumococcal CRM(197) conjugate vaccine co-localizes with MHC II on the antigen processing cell surface. Vaccine (2009) 27:3137–44.10.1016/j.vaccine.2009.03.064 19446183 [OpenAIRE] [PubMed] [DOI]
15 Smith KG Light A Nossal GJ Tarlinton DM. The extent of affinity maturation differs between the memory and antibody-forming cell compartments in the primary immune response. EMBO J (1997) 16:2996–3006.10.1093/emboj/16.11.2996 9214617 [OpenAIRE] [PubMed] [DOI]
Related research
- Novartis (Switzerland) Switzerland
1 Willis NJ. Edward Jenner and the eradication of smallpox. Scott Med J (1997) 42:118–21.
2 Lakhani S. Early clinical pathologists: Edward Jenner (1749-1823). J Clin Pathol (1992) 45:756–8.10.1136/jcp.45.9.756 [OpenAIRE] [DOI]
3 Kaushik DK Sehgal D. Developing antibacterial vaccines in genomics and proteomics era. Scand J Immunol (2008) 67:544–52.10.1111/j.1365-3083.2008.02107.x 18397199 [OpenAIRE] [PubMed] [DOI]
4 Rappuoli R Miller HI Falkow S. Medicine. The intangible value of vaccination. Science (2002) 297:937–9.10.1126/science.1075173 [OpenAIRE] [DOI]
5 Plotkin SA. Vaccines: past, present and future. Nat Med (2005) 11:S5–11.10.1038/nm1209 15812490 [OpenAIRE] [PubMed] [DOI]
6 Rappuoli R. From Pasteur to genomics: progress and challenges in infectious diseases. Nat Med (2004) 10:1177–85.10.1038/nm1129 15516917 [OpenAIRE] [PubMed] [DOI]
7 Makela PH Peltola H Kayhty H Jousimies H Pettay O Ruoslahti E Polysaccharide vaccines of group A Neisseria meningtitidis and Haemophilus influenzae type b: a field trial in Finland. J Infect Dis (1977) 136(Suppl):S43–50.10.1093/infdis/136.Supplement.S43 [OpenAIRE] [DOI]
8 Peltola H Makela H Kayhty H Jousimies H Herva E Hallstrom K Clinical efficacy of meningococcus group A capsular polysaccharide vaccine in children three months to five years of age. N Engl J Med (1977) 297:686–91.10.1056/NEJM197709292971302 408682 [OpenAIRE] [PubMed] [DOI]
9 Lesinski GB Westerink MA. Novel vaccine strategies to T-independent antigens. J Microbiol Methods (2001) 47:135–49.10.1016/S0167-7012(01)00290-1 11576678 [PubMed] [DOI]
10 Conaty S Watson L Dinnes J Waugh N. The effectiveness of pneumococcal polysaccharide vaccines in adults: a systematic review of observational studies and comparison with results from randomised controlled trials. Vaccine (2004) 22:3214–24.10.1016/j.vaccine.2003.08.050 15297076 [OpenAIRE] [PubMed] [DOI]
11 Lepow ML Goldschneider I Gold R Randolph M Gotschlich EC. Persistence of antibody following immunization of children with groups A and C meningococcal polysaccharide vaccines. Pediatrics (1977) 60:673–80.411104 [PubMed]
12 Peltola H Kayhty H Virtanen M Makela PH. Prevention of Hemophilus influenzae type b bacteremic infections with the capsular polysaccharide vaccine. N Engl J Med (1984) 310:1561–6.10.1056/NEJM198406143102404 6610125 [OpenAIRE] [PubMed] [DOI]
13 Makela PH Kayhty H. Evolution of conjugate vaccines. Expert Rev Vaccines (2002) 1:399–410.10.1586/14760584.1.3.399 [OpenAIRE] [DOI]
14 Lai Z Schreiber JR. Antigen processing of glycoconjugate vaccines; the polysaccharide portion of the pneumococcal CRM(197) conjugate vaccine co-localizes with MHC II on the antigen processing cell surface. Vaccine (2009) 27:3137–44.10.1016/j.vaccine.2009.03.064 19446183 [OpenAIRE] [PubMed] [DOI]
15 Smith KG Light A Nossal GJ Tarlinton DM. The extent of affinity maturation differs between the memory and antibody-forming cell compartments in the primary immune response. EMBO J (1997) 16:2996–3006.10.1093/emboj/16.11.2996 9214617 [OpenAIRE] [PubMed] [DOI]